The thesis
PanicFade v4 bets that negative headline shocks get overdone. When a large cap takes a sentiment hit below -0.4 while already oversold — RSI14 under 35 and trading below its SMA20 — the strategy buys into the panic and sizes up as it deepens. It exits on reversion (RSI14 above 50 or a reclaim of the SMA20) and hard-stops on fresh lows under continued negativity, treating that as a genuine fundamental break rather than noise. The approach is grounded in recent sentiment-feedback research (arXiv:2509.11970) and the broader negative-media overreaction literature, and it runs on a focused 24-name universe of mega-cap staples, financials, healthcare, and tech.
Validation holds up
This is the strongest part of the story. Across four walk-forward folds spanning September 2021 to August 2026, every fold was positive — 1.6%, 3.88%, 10.14%, and 21.7% — and the out-of-sample segment returned 21.7% at a 2.44 Sharpe. The probabilistic Sharpe ratio is a high 0.985 and the deflated Sharpe, which penalizes the 27 trials run, still clears at 0.56. Four-for-four positive folds through a 2022 bear market and a subsequent recovery is a meaningful robustness signal, not a single lucky regime.
But read the full backtest honestly
The headline 37.93% return was earned over 1,233 trading days, which works out to a 6.79% CAGR — respectable but not spectacular. The aggregate Sharpe of 0.96 and a 9.3% max drawdown describe a steady, moderate-edge strategy rather than a high-octane one. Turnover is heavy at 5,807%, generating 530 trades and 530 in fees; the 62.88% win rate suggests many small, frequent wins, which is consistent with mean-reversion but leaves the net edge sensitive to transaction costs. Fold 1 is the cautionary data point: just 1.6% at a 0.19 Sharpe through the 2022 drawdown, a reminder that fading panic works poorly when the panic is correct.
Recent live activity
The live paper book has been quiet. Six scheduled runs between September 23 and 30 produced a single execution — a 2-share UNH buy on the 23rd — with every other day flat. Earlier September saw more action: buys in NKE, HD, and BAC, and a round-trip in WMT (bought at 103.12, sold at 107.48). Portfolio value has drifted down from roughly $9,923 to $9,810 over the quiet stretch, sitting modestly below the implied $10,000 base, with over half the book ($5,765) parked in cash.
Verdict
PanicFade v4 is one of the better-validated strategies on the platform, with a coherent, literature-backed thesis and clean walk-forward evidence. The honest caveats are a mid-single-digit annualized return, cost-heavy turnover, and a demonstrated soft spot in genuine bear regimes. The current cash-heavy, low-activity posture suggests few names are hitting the entry bar right now — fine for a patient contrarian, but worth watching that the live record eventually tracks the backtest.